Enliven Therapeutics Inc. reported a net loss of $0.48 per share for the fourth quarter of 2025, missing the consensus estimate of $0.38 per share. The company’s full‑year loss was $1.83 per share, driven by a $103.7 million net loss and the absence of product revenue. Cash, cash equivalents and marketable securities totaled $462.6 million as of December 31 2025, giving the company a runway into the first half of 2029.
The company’s Phase 1b ENABLE trial of ELVN‑001, a next‑generation BCR‑ABL inhibitor for chronic myeloid leukemia, produced encouraging early results. Cumulative major molecular response (MMR) rates reached 47 % at 24 weeks in the 80 mg cohort and 69 % in the combined 60 mg/120 mg cohort. At the 24‑week mark, 38 % of patients in the 80 mg cohort and 53 % in the 60 mg/120 mg cohort achieved MMR, a performance that compares favorably to precedent Phase 1 trials of approved BCR‑ABL tyrosine‑kinase inhibitors.
"2025 was a year of meaningful progress as we advanced ELVN‑001 toward a Phase 3 pivotal clinical trial," said CEO Rick Fair. "As we move into 2026, we are entering one of the most active and transformative periods in Enliven’s history – with an important data readout, key regulatory interactions, and the planned initiation of our ENABLE‑2 pivotal trial." Chief Medical Officer Helen Collins added, "Our data continue to demonstrate that ELVN‑001 has the potential to be the best‑in‑class active‑site TKI for the treatment of CML and an important treatment option across all lines of therapy." Co‑founder and former CEO Sam Kintz noted, "We are pleased to report that during the quarter, we completed enrollment of the randomized Phase 1b portion of the ENABLE trial and achieved key readiness milestones across multiple geographies, positioning us to rapidly launch our Phase 3 trial globally next year."
Enliven reiterated its 2026 guidance, maintaining a focus on completing the Phase 3 ENABLE‑2 trial while preserving its strong cash position. The company’s guidance signals confidence that the upcoming pivotal study will be launched in the second half of 2026 and that the current cash reserves will support the program through the first half of 2029.
The earnings miss can be attributed to higher research and development and general‑administrative expenses, partly driven by a CEO transition that increased G&A costs. Despite the loss, the company’s lack of product revenue is typical for a clinical‑stage biopharma, and the positive Phase 1b data provide a strong foundation for future milestones. Compared with the prior year, the full‑year net loss of $103.7 million is larger than the $89.0 million loss reported in 2024, reflecting intensified investment in the ELVN‑001 program.
Overall, Enliven’s financial position remains robust, and the early clinical signals for ELVN‑001 suggest a potentially competitive product in the chronic myeloid leukemia market. The company’s guidance and cash runway position it well to execute the next phase of development and to navigate the regulatory pathway toward eventual commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.